SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that management will participate in the following investor conferences: Guggenheim Healthcare Innovation ConferencePrese
Find the latest Lisata Therapeutics, Inc. (LSTA) stock quote, history, news and other vital information to help you with your stock trading and investing.
Detailed price information for Lisata Therapeutics Inc (LSTA-Q) from The Globe and Mail including charting and trades.
LIBERTY CORNER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company, today announced that the United States Patent and Trademark Office (“USPTO”) has granted a new Method of Use patent for certepetide [U.S. Patent No. 12,751,991] for the treatment of pancreatic cancer and other solid tumors, expiring May 2041. The newly issued patent, titled “Methods for Treating Pancreatic Cancer and Other Solid Tu
Marea Therapeutics, a subsidiary of Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), said data from the Phase 2b TYDAL study of its lead candidate MAR001 will be presented in a late-breaking science session at the American Heart Association Scientific Sessions 2026 in Chicago. MAR001 is an...
Late-breaking presentation will highlight Phase 2b clinical data for MAR001, a potential first-in-class antibody targeting ANGPTL4 designed to lower triglycerides and improve metabolic functionSOUTH SAN FRANCISCO and LIBERTY CORNER, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-g
Detailed price information for Lisata Therapeutics Inc (LSTA-Q) from The Globe and Mail including charting and trades.
Marea’s acquisition by Lisata, alongside a $225 million financing deal, will back development of a pair of medicines in mid-stage testing for cardiovascular and endocrine conditions.
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has acquired Marea Therapeutics, a clinical-stage biotech developing next-generation medicines for cardioendocrine diseases. The companies also entered a private placement financing agreement expected to raise approximately $225 million in gross...
Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseases Marea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG) currently in Phase 2b and MAR002 for the treatment of acromegaly which is advancing to a Phase 2 study Concurrent financing of $225 million from leading life sciences investors and other institutional investors projected to fund operations into 2028 LIBERTY CORNER, N.J., Sept. 17,
This is the newest page. Registered accounts read further back.